Coherus Shares Tumble Following Quarterly Earnings Report

Coherus BioSciences experienced significant selling pressure on Friday as its stock price declined 5.56 percent to close at $1.19. The downward movement came in response to the company's latest financial results, which fell short of market projections for both revenue and earnings per share.

The biopharmaceutical company has finalized its transformation into a pure-play oncology business after divesting its biosimilars portfolio during the second quarter. This strategic repositioning allows Coherus to concentrate exclusively on developing innovative cancer treatments, though the transition period has presented financial challenges.

Third-quarter 2025 performance metrics revealed substantial deviations from analyst expectations. Revenue reached $11.6 million, notably below the anticipated $13.36 million. The company reported a per-share loss of $0.33, slightly wider than the projected $0.32 deficit.

LOQTORZI Emerges as Bright Spot

Despite the overall disappointing figures, Coherus's cancer therapeutic LOQTORZI demonstrated impressive market traction. The drug generated a 12 percent revenue increase compared to the previous quarter and achieved a remarkable 92 percent growth year-over-year.

Should investors sell immediately? Or is it worth buying Coherus BioSciences?

The company's financial position shows $198 million in cash reserves as it pursues ambitious targets for its flagship oncology product. Management has established a goal of generating $150-200 million in LOQTORZI revenue by mid-2028, which would require maintaining consistent quarterly growth between 10 and 15 percent.

Pipeline Developments Show Promise

Research and development efforts continue to advance, with recent Phase 1 trial data for CHS-114 indicating positive outcomes. The treatment demonstrated tumor-specific TREG depletion and enhanced CD8 T-cell infiltration. Notably, early response was observed even in a heavily pretreated head and neck cancer patient.

The coming year represents a critical validation period for Coherus's strategic direction. Key data readouts for both CHS-114 and casdozokitug are scheduled for 2026, which will determine whether the company's focused oncology approach can deliver sustainable growth or if current financial pressures will persist.